soulofwolf: that's always the conundrum of a small biotech. Probably what big pharma was offering for cotara would be considered an insult by PPHM investors. So, management holds out. If there's a healthy market, management will raise the $ through things like we've been doing (selling shelf shares); however, if we enter a protracted bear market (as we could very well be in), big pharma can disguise it's greed through collusion with hedgies doing their naked shorting (and the SEC doesn't give jacks&%@).
News 
Market Data 
Discover 
AI
